# Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

> **NCT05201612** · PHASE2 · UNKNOWN · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05201612
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-07
- **Primary completion:** 2024-09
- **Final completion:** 2025-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201612, "Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05201612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*